A Phase I study of ET-743 in combination with pegylated liposomal doxorubicin (PLD) in patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer

Trial Profile

A Phase I study of ET-743 in combination with pegylated liposomal doxorubicin (PLD) in patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 14 Jun 2016 New trial record
    • 04 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top